Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or Biogen Inc.

Teva vs. Biogen: A Decade of Gross Profit Battle

__timestampBiogen Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014853228800011056000000
Thursday, January 1, 2015952340000011356000000
Friday, January 1, 2016997010000011859000000
Sunday, January 1, 20171064390000010825000000
Monday, January 1, 2018116366000008296000000
Tuesday, January 1, 2019124225000007536000000
Wednesday, January 1, 2020116394000007725000000
Friday, January 1, 202188720000007594000000
Saturday, January 1, 202278951000006973000000
Sunday, January 1, 202373022000007646000000
Monday, January 1, 202496759000008064000000
Loading chart...

Igniting the spark of knowledge

A Decade of Gross Profit: Teva vs. Biogen

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Biogen Inc. have been pivotal players. From 2014 to 2023, these giants have showcased their prowess in generating gross profit. Teva, with its robust generic drug portfolio, initially led the race, peaking in 2016 with a gross profit of approximately 11.9 billion. However, Biogen, renowned for its innovative therapies, surged ahead in 2019, achieving a gross profit of around 12.4 billion, marking a 24% increase from 2014.

The subsequent years saw a decline for both, with Biogen's gross profit dropping by 41% by 2023, while Teva's fell by 36%. This trend reflects broader industry challenges, including patent cliffs and pricing pressures. As the pharmaceutical sector evolves, the strategic maneuvers of these companies will be crucial in determining their future financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025